research
STRIDE study: GLP1s vs peripheral artery disease (PAD)
Walk farther with GLP1s -- results from the STRIDE study show Semaglutide effective for treating Peripheral Artery Disease (PAD)
chemical:semaglutide
company:novo-nordisk
Novo Nordisk offers cheaper Wegovy
Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.
chemical:semaglutide
Semaglutide removed from shortage list
It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.
category:news
HIMS to offer Liraglutide after shortage rule changes
HIMS leans into Liraglutide as a replacement for Semaglutide in the face of shortage rule changes. Is it good enough?
chemical:semaglutide
Semaglutide & Liraglutide continue to be effective
Semaglutide and Liraglutide continue to be researched and studied and produce positive results for weight loss and medical outcomes.
category:side-effects
Semaglutide's link to blinding disease (NAION)
We explore the link between blinding disease/vision loss and Semaglutide, as reported by medical research.
category:factsheet
Patent expirations for GLP1 Receptor Agonists
How long will we have to wait for generic versions of GLP1 drugs? We take a look at patent expiry dates for the most popular brands & GLP1 formulations.
includes:study
Are GLP1 side effects all the same?
Do some GLP1s have less negative side effects? They work the same, but can affect you differently -- let's look at the research.
chemical:semaglutide
24% Less kidney disease risk with Semaglutide (Ozempic)
Can we trust research funded by Novo Nordisk which found a 24% decrease in kidney disease risk for people on Semaglutide (Ozempic)?
drug:ozempic
Semaglutide (Ozempic) vs Tirzepatide (Mounjaro)
Learn the major differences between Ozempic (Semaglutide) and Mounjaro (Tirzepatide)